Phase 2 To Determine Safety And Efficacy Of A mAB CKI Combo In Relapse Refractory Multiple Myeloma (RRMM)
Discover how we managed cell isolation and counts among other routine and speciality tests for a large Relapse Refractory Multiple Myeloma study over 11,000 samples managed.
Tests including FCM, PBMC isolation and count, FISH
Phase 1 Dose Escalation Study With A Bispecific Antibody In Relapse Refractory Multiple Myeloma (RRMM)
Discover how we manage routine and specialty test for a Phase 1 study
Phase 3 CAR-T vs SOC in Relapse Refractory Multiple Myeloma (RRMM)
Discover how effective we are in immunophenotyping for a Car-T therapy take a look at this case study
Case Study: How Cerba Research Helped Advance a Phase IIB Study in the Middle of a Pandemic and Brexit
How To Improve the Patients Experience in IO Clinical Trials – with the Gustave Roussy Institute
Tech Transfer IFE Reflex Assay China
A Biotech Company in China required our scientific expertise for the Tech Transfer of IFE Reflex Assay on a clinical trial in the Oncology field (Relapsed or Refractory Multiple Myeloma). Cerba Research was not the Biotech’s central or specialty laboratory on the study but brought in for our expertise on the tech transfer.
Download the case study to read more.
Pediatric Phase I/II Clinical Trial on Mucopolysaccharidosis type III (MPSIIIA)
Lab support for a global pediatric trial for the rare genetic neurodegenerative disorder, Mucopolysaccharidosis type III. Cerba Research provided safety testing, sample management, and specialized testing in our histology lab. Read the case study to discover more details.
Pediatric Phase I/II/III Study in X-Linked Myotubular Myopathy (XLMTM)
Lab support for a global pediatric trial for the rare neuromuscular disease, Myotubular Myopathy. Cerba Research provides safety testing, PBMC isolation, biomarkers, and sample management for the clinical trial. Read more on the challenges and solutions in the case study.
Lab Support for the Largest Global Phase III NASH Study to Date
10-Day Study Start & Custom Test Kit Build at the Height of a Pandemic
Cerba Research initiated custom kit building & distribution for an infectious disease study, during the COVID-19 pandemic, in 10 days. A typical timeline is 8 weeks.